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OBJECTIVES We studied the effects of rate and some cardioactive drugs on the atrial surface electrocar-
diogram (ECG).
BACKGROUND In atrioventricular block, atrial surface ECG is unmasked. The effect of rate alone permits
detection of the effect of other exogenous stimulations such as drugs in the presence of rate
alterations.
METHODS High fidelity, high gain ECG leads I, II and III were recorded from 51 patients with heart
block. Durations of P and Ta waves and the total PTa interval were measured from
nonconducted atrial events.
RESULTS No relationship was found between sinus cycle length and PTa, P or Ta in 31 patients. In 20
patients, progressively decreasing the atrial pacing cycle length from 853 ms to 381 ms
resulted in a linear reduction of the PTa interval from 444 to 291 ms (rho 5 0.76, slope 5
0.24). This was largely due to shortening of Ta. A linear rate correction formula was derived:
corrected PTa 5 PTa 2 0.24 (PP 2 1000). Atropine (0.02 mg/kg) shortened the PP interval
(p , 0.001) and the PTa interval (p , 0.01). Propranolol (0.1 mg/kg) prolonged the PP
interval (p , 0.001) but did not alter the PTa interval. Neither disopyramide (2.0 mg/kg) nor
flecainide acetate (2.0 mg/kg) altered the PP interval, but both prolonged the PTa interval
(p , 0.001). This was largely due to P wave lengthening after flecainide (p , 0.001) and to
Ta prolongation after disopyramide (p , 0.001).
CONCLUSIONS In heart block, PTa, P and Ta waves can be measured reliably. The effects of pacing and some
antiarrhythmic drugs on the atrial myocardium are similar to those known at the ventricular
level. (J Am Coll Cardiol 1999;33:358–65) © 1999 by the American College of Cardiology
Compared with the QRS complex, the electrocardiographic
(ECG) deflection due to atrial depolarization is small in
both amplitude and area. Atrial repolarization is usually
hidden by the ensuing QRS complex (1). Atrioventricular
(AV) block may be used as a model to study atrial depolar-
ization and repolarization (2–4). We developed a high gain,
high fidelity technique of recording ECG atrial activity in
patients with 2:1 or complete AV block.
The properties of atrial repolarization might give rise to
atrial arrhythmias in the same way as ventricular repolariza-
tion relates to ventricular arrhythmia (5). It is therefore
important to determine the normal variations of the atrial
ECG complex, the PTa interval, to recognize abnormalities.
Changes in heart rate may result in changes in PTa interval
duration and morphology. The knowledge of the effect of
rate alone on the atrial surface ECG permits detection of
the effect of drugs or any other physiopathologic interven-
tion in the presence of related rate alteration.
Clinical determination of the effect of drugs on the
ventricular myocardium is usually based on changes induced
in ECG activity, but similar studies on the atrial myocar-
dium have not been undertaken. We selected atropine, an
antimuscarinic drug the effect of which on the human atrial
myocardium is still controversial (6–8), and propranolol, a
nonselective beta-adrenoceptor blocking agent. Disopyr-
amide, a class Ia antiarrhythmic drug, and flecainide acetate,
a class Ic agent (9), are both effective in converting atrial
fibrillation to sinus rhythm when given intravenously
(10,11), making therefore their effect on surface atrial ECG
of interest.
METHODS
Patients. The study population consisted of 51 patients (34
men) aged from 26 to 86 (mean 61) years. Thirty-eight of
them suffered with complete 3rd degree AV block and 13
with 2nd degree Mo¨bitz II AV block. The cause of their
conduction defect was degenerative in 39, congenital in 2,
therapeutic catheter ablation of AV conduction in 9 and
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aortic valve replacement in 1. All were awaiting implanta-
tion of a permanent pacemaker system. None of the patients
was suffering from hypertension or ischemic heart disease.
Their hearts were radiologically within normal limits for
their age. The echocardiographic examination revealed no
enlargement or other abnormality of the atria. Mitral and
tricuspid valves were normal. None of the patients had
abnormal atrial depolarization and repolarization intervals
in sinus rhythm; patients with interval durations
P . 125 ms and PTa . 465 ms were excluded (3,12).
Patients whose morphology of atrial depolarization and
repolarization were biphasic, bifid, abnormally slurred or of
an electrical gradient very different from 0 were also ex-
cluded. None of them had taken any antiarrhythmic med-
ication for at least five elimination half-lives before the
recordings were made. Twenty-four–hour ECG monitor-
ing confirmed the absence of atrial arrhythmias except in the
nine patients who had undergone His bundle ablation as a
therapeutic measure for paroxysmal atrial flutter and atrial
fibrillation and recurrent paroxysmal sinus tachycardia.
All patients had a transvenous 5-F or 6-F bipolar pacing
electrode catheter positioned in the apex of the right
ventricle, and 20 of these patients also had a temporary
transvenous J pacing electrode catheter placed in the right
atrial appendage. All studies were done with the patient
lying supine and with the ventricle paced on demand mode
at 40 bpm after informed consent was obtained.
Validation study. The technique was validated on 17
patients.
Study in sinus rhythm. Atrial surface ECG recordings
were obtained from 31 patients in sinus rhythm at rest. The
durations of the PTa, P and Ta intervals were measured and
correlated with the sinus PP interval.
Atrial pacing study. In the group of 20 patients with atrial
pacing electrodes, the effect of pacing the atrium at pacing
intervals varying between 863 and 381 ms (rates varying
between approximately 70 and 150 bpm) was determined.
Each patient was paced at two to nine different rates. The
atrium was paced for 3 min at each rate before any recording
was made to allow steady state to be reached (12,13). The
PTa and Ta intervals and the P wave duration were
correlated with the paced PP intervals. A linear regression
equation was derived to predict the effect of changes in PP
intervals on PTa, P and Ta.
Drug administration study. Propranolol was administered
at a dose of 0.1 mg/kg to 8 patients, atropine, at a dose of
1.2 mg to 12 patients, disopyramide at a dose of 2 mg/kg
(10) to 9 patients and flecainide at a dose of 2 mg/kg (11) to
10 patients. To obtain steady state, all drugs were admin-
istered intravenously, over 2 min for atropine and over
15 min for propranolol, disopyramide and flecainide.
Method. Standard bipolar leads I, II and III of the con-
ventional surface ECG were recorded directly onto half-
inch FM magnetic tape using a Racal store 7 recorder. The
amplification through a Biodata low noise physiologic
amplifier ranged from 1,000 to 10,000 times (a factor of 10
to 100 times the gain used for standard ECG recordings),
depending on the input signal level. Extraneous noise was
reduced by collecting the signals over a narrow frequency
band of 0.16 to 30 hertz (3 dB points). For analysis, the
signals were transferred to computer memory via a 12-bit
analog to digital converter at a sampling rate of 256 samples
per second. Once in the computer memory, good quality,
low noise recordings were displayed directly on a Tektronix
4010 graphics terminal. In occasional cases, when the
recorded signals, particularly the repolarization Ta wave,
were too small in amplitude or when reduction of myogenic
noise or mains interference was necessary, it was possible to
subject the signals to further computer analysis, providing
further amplification (up to a factor of 4) and/or further
digital filtration (low pass filter) (Fig. 1).
The total duration of the atrial ECG event, the PTa
interval, was measured from the beginning of the P wave
Abbreviations and Acronyms
AV 5 atrioventricular
CV 5 coefficient of variation
ECG 5 electrocardiogram/electrocardiographic
MAP 5 monophasic action potential
Figure 1. Lead I of the surface electrocardiogram as recorded (top
panel), with further amplification (middle panel) and with further
amplification and filtration (bottom panel).
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(atrial depolarization) to the end of the Ta wave (atrial
repolarization). The end of the P wave (and the beginning
of the Ta wave) was arbitrarily defined as the point at which
the ECG trace crossed the isoelectric line (Fig. 1). Only
complete PTa complexes, not interrupted by a ventricular
QRS complex or T wave or deformed by an artifactual
change of the baseline, were measured. Measurements were
made from the lead with the clearest PTa complex recorded
in each patient. Care was taken to measure the same lead in
any one patient. For each recorded value of PTa, five
unencumbered PTa complexes were measured to determine
the coefficient of variation (CV) of the measurements.
The coefficient of intraobserver variation for one observer
measuring the recordings of 10 patients in sinus rhythm on
four different occasions and the variance attributable to the
different measurement times by the same observer were
assessed. Six different observers measured recordings from
the same four patients to assess the interobserver variability.
Intraindividual repeatability (14) was tested on 12 patients
by recording their atrial ECG in the same conditions on two
occasions. To assess the effect of drugs on atrial depolariza-
tion and repolarization, the recordings were performed
immediately before drug administration and again at the
end of the injection of each drug.
PTa intervals were corrected for rate by the use of Bazett’s
hyperbolic correction factor designed for the ventricular QT
intervals and adapted to the atrial intervals and by a linear
correction derived by pacing the atrium of 35 patients.
Statistical analysis. Data are expressed as mean and stan-
dard deviation. Between- and within-observer variations
were tested using one random factor analysis of variance,
and the coefficient of variation was used to express repro-
ducibility. For correlation analysis between two variables,
parametric Pearson product–moment correlation coefficient
r was calculated. In cases when each data point was not
independent of the other (when several data points derived
from the same patient), the nonparametric Spearman rank
correlation coefficient rho was calculated (15). Student
paired t test was used to assess the effect of the different
drugs on the PP, PTa, Ta and P intervals. This test was also
performed on the values corrected for heart rate. All tests
were two tailed, and the statistical significance level was set
at 5%.
RESULTS
Validation study. Variation in the measurements, assessed
as stated above, varied from 1% to 3% for the full PTa
interval. The P wave duration CV varied between 0% and
11% and the Ta interval CV, between 1.5% and 4.5%. The
coefficient of intraobserver variation for one observer mea-
suring the recordings of 10 patients in sinus rhythm on four
different occasions varied between 1% and 3%. The variance
attributable to the different measurement times by the same
observer was not significant (F test 5 1.04, p 5 0.39, NS).
The mean interobserver CV, by six different observers
measuring the same four patients’ recordings, was ,3.5% in
all cases. The variance attributable to observer was not
significant (F test 5 0.71, p 5 0.56, NS). Intraindividual
repeatability (8) tested on 12 patients by recording their
atrial ECG in the same conditions on two occasions showed
no “occasion” effect or systematic error (t test 5 0.20, p 5
0.85, NS).
Study in sinus rhythm. There was no significant correla-
tion between atrial ECG interval duration (PTa, P, Ta) and
atrial sinus cycle length.
Atrial pacing studies. Increasing the pacing rate reduced
the PTa interval mainly by shortening the repolarization
segment, Ta. There was a good linear correlation of the
atrial ECG intervals PTa and Ta with the pacing interval
PP (Figs. 2 and 3). There was no obvious relationship
between P wave duration and pacing intervals (Fig. 4).
From the linear regression of PTa interval upon PP
interval was derived a correction equation for the PTa
interval which accounted for the effect of atrial rate. To
Figure 2. Correlation between PTa and atrial paced cycle length
(PP) in 20 patients (n 5 103 points); rho 5 0.76, p , 0.001,
slope 5 0.24, intercept 5 243 ms.
Figure 3. Correlation between Ta and atrial paced cycle length
(PP) in 20 patients (n 5 103 points); rho 5 0.62, p , 0.001,
slope 5 0.24, intercept 5 124 ms.
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correct for changes in PP, all values of PTa are expressed as
though PP was 1,000 ms (60 beats per minute):
Corrected PTa 5 PTa 2 0.24 ~PP 2 1000!.
Drug study. Propranolol slowed the atrial rate, and atro-
pine resulted in an increase in atrial rate (Fig. 5 and 6).
Neither flecainide nor disopyramide had a significant effect
on rate (Fig. 6).
Propranolol did not significantly alter any of the uncor-
rected atrial intervals, but atropine significantly decreased all
three intervals (Fig. 7). The PTa interval was significantly
increased by both disopyramide and flecainide, but disopyr-
amide acted mainly by increasing the Ta interval, whereas
flecainide acted by increasing the P wave duration (Fig. 7).
Correction of the PTa interval for drug-induced rate
changes using both the Bazzet’s hyperbolic formula and the
linear regression equation produced similar results; intervals
varied in the same direction with each different drug.
Propranolol significantly decreased the PTa interval,
whereas atropine had no significant effect on it. Disopyr-
amide and flecainide significantly prolonged the PTa inter-
val (Fig. 8).
DISCUSSION
Study in sinus rhythm. Atrial intervals did not correlate
with PP intervals in 31 patients in whom, of course,
interindividual variability in refractoriness and therefore in
PTa duration may be expected. Moreover, although all the
patients were selected as having normal atria, six of them
had documented atrial arrhythmias. This may also explain
the lack of linear correlation. Hayashi et al. (3) did find a
linear correlation between PTa and PP including only one
point for each of 25 patients in atrial sinus rhythm with AV
block of whom 20 had no significant cardiovascular diseases
and 5 had severe cardiovascular conditions such as ischemia
and arrhythmia. Kesselman et al. (16) measured atrial
deflections from the surface ECG of 36 patients and
concluded that a linear relationship existed between PTa
interval and PP at rates varying between 60 and 300 bpm,
with a slope of 0.34 and an intercept of 140 ms. These
authors made 50 measurements on the ECGs obtained
from 35 patients and 24 measurements on the ECG of a
single patient. Three recordings were made at atrial rates of
200 and 300 bpm, one of which was in paroxysmal atrial
tachycardia and two in atrial flutter. Clearly, the linear
correlation might have been influenced by the inclusion of
several measurements recorded from the same patient.
Including patients with atrial rates of 200 and 300 bpm,
which represent a series of depolarizations with no repolar-
Figure 4. Correlation between P and atrial paced cycle length (PP)
in 20 patients (n 5 103 points); rho 5 0, p 5 NS.
Figure 5. Effect of intravenous propranolol (0.1 mg/kg) on the
atrial surface electrocardiogram. Before propranolol: P 5 106 ms,
Ta 5 289 ms. On propranolol: P 5 102 ms, Ta 5 319 ms. C 5
corrected.
Figure 6. Effect of propranolol, atropine, disopyramide and fle-
cainide on the atrial cycle length (PP).
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ization, is also disputable, although it increases the range of
sinus rates.
The monophasic action potential reflects cellular refrac-
toriness (17,18). The PTa interval is the spatial summation
of all atrial electrical events. The PTa and Ta intervals are
only an approximation of the repolarization time and are not
a measure of either cellular action potential or monophasic
action potentials (MAPs) (12). However, a shortening of
the right atrial MAP with decreasing cycle length in
individual patients has earlier been pointed out by Shabetai
et al. (19), but is not evident in the report by Korsgren et al.
(20). Olsson (21) found a linear correlation between atrial
monophasic action potential duration and the PP interval in
a group of 12 patients in sinus rhythm at rest. However,
differences between measurements in the duration of the
right atrial MAP between patients as well as in the same
patient were obvious; he concluded that there was a wide
distribution of the refractory periods in human atria, which
can explain the lack of correlation found in our study.
Atrial pacing study. The rate-related variation of the PTa
interval at different pacing cycle lengths has not been
studied previously. The PTa duration is a reflection of atrial
refractoriness (12). Correlating the atrial interval duration
with the pacing cycle length therefore gives an indication of
the variation in atrial refractoriness with rate. In this study,
increasing atrial pacing rate decreased the PTa interval
mainly by reducing the duration of repolarization. This is
concordant with the findings of Denes et al. (22), who
reported that atrial effective and functional refractory peri-
ods decreased with pacing cycle length in 11 patients with
normal atria. Furthermore, Attuel et al. (23) demonstrated
a relationship between atrial vulnerability to arrhythmias
and failure of the atrial refractory period to shorten with
increasing rate.
The P wave duration is little affected by rate. This is
analogous to what has been described at the ventricular level
(24), where heart rate changes have little or no effect on
ventricular depolarization but substantially alter the JT
interval.
At the ventricular level, in man, in vitro work on action
Figure 7. Effect of propranolol, atropine, disopyramide and fle-
cainide on the atrial surface electrocardiographic intervals, PTa, P
and Ta.
Figure 8. Effect of propranolol, atropine, disopyramide and fle-
cainide on the PTa interval corrected for rate using the linear
regression equation (top panel) and Bazett’s hyperbolic formula
adapted to the atrium (bottom panel).
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potential duration (25) and in vivo studies on monophasic
action potentials (26) have shown that the steady state
duration of ventricular repolarization correlates linearly with
the paced cycle length over physiologic ranges and flattens at
cycle lengths greater than 900 ms. This is consistent with
the linear relation found for the atria in the present study, in
which cycle lengths varied between 381 and 863 ms. The
correction equation for cycle length derived from this should
obviously be used cautiously at cycle lengths greater than
836 ms or smaller than 381 ms.
At the atrial level, the end of depolarization and the onset
of recovery overlap, making atrial activation time plus
recovery time greater than the PTa interval. Nonetheless
PTa interval reflects atrial electrophysiologic properties in
the same way as the QT interval does for the ventricles. In
1920, Bazett (27) related ECG ventricular systole to the
cycle length and proposed the hyperbolic formula QT 5 K
=RR, where K is a constant and RR the cycle length in
seconds. This relation was derived from adult subjects
before and during exercise as well as from infants. Later, by
selection of more homogeneous groups, a linear equation
(28) and a logarithmic equation (29) became widely ac-
cepted.
Boyett and Jewell (30) showed ventricular action po-
tential duration to be a function of rate; depolarization
was not rate dependent, but repolarization shortened
with increasing rates as earlier described by Khan and
Simonson (24). Although Atwell et al. (13) suggested
that the QT interval duration adaptation to heart rate is
purely frequency dependent, Rickard and Norman (31)
contradicted this hypothesis by producing evidence that
atrial pacing shortens the QT interval less than physio-
logic exercise at comparable heart rates. They suggested
that circulating catecholamines might account for this
difference. Milne et al. (32) showed that shortening of
the QT interval can occur during exercise in the absence
of change of heart rate and confirmed that this effect is
mediated by changes in the autonomic nervous system
(33,34) and by an increase in the level of circulating
catecholamines. This explains the steeper slope of the
linear correlation between QT and RR when the cycle
length shortens due to exercise than when atropine or
pacing (29,31) are used to increase rate. Based on these
observations, Milne (32) showed that the commonly used
correction devices, in particular Bazett’s formula, are
unsuitable for QT interval changes induced by atrial and
ventricular pacing. Although autonomic innervation is
very different at atrial and ventricular levels, the atria
being largely under the influence of parasympathetic
tone, it is likely that the strong linear correlation found
here between PTa and Ta and atrial cycle length obtained
by pacing the right atrium cannot be extended to other
circumstances such as exercise.
Patients. This study was conducted to determine the effect
of rate on the duration of depolarization and repolarization
of the normal atrium. Although the patients were selected
accordingly, they could have had underlying atrial disease. It
is well known that there is a higher incidence of sinus node
dysfunction in patients with AV block (31). In six patients,
AV block had been produced artificially as a therapeutic
measure for atrial arrhythmia. Olsson et al. (35) showed that
a short atrial refractory period (measured by the technique
of the monophasic action potentials) was present in some
patients failing to maintain sinus rhythm after direct current
conversion of atrial fibrillation. In brief, Wyndham et al.
(36) demonstrated that decrease in cycle length potentiates
atrial vulnerability to atrial tachyarrhythmia. Attuel et al.
(23) suggested that atria with poor or absent rate adaptation
of the refractory period are prone to atrial flutter or
fibrillation. Dispersion of atrial refractoriness is known to
predispose to arrhythmia (17,37); a short refractory period
allows development of tachyarrhythmia owing to the pos-
sibility of early excitation and initiation of new depolariza-
tion in adjacent muscle cells with different refractoriness.
The PTa interval records the sum of the atrial electrical
phenomena. The six patients with atrial arrhythmia did not
have particularly long or short repolarization phases.
Drug study. It is thought that the atria are predominantly
under parasympathetic control (17). In man, variable or no
effect of atropine on the atrial refractory period has been
reported (6,7). Dhingra et al. (8) showed that atropine
shortens atrial functional and effective refractory periods,
facilitating conduction, and implied that vagal stimulation
prolongs the refractory period in man.
Acetylcholine shortens the duration of the action poten-
tial in isolated myocardial preparations, but vagal stimula-
tion prolongs the atrial monophasic action potential in man
due to the decrease in heart rate. Thus, the effect of
bradycardia compensates the direct vagal effect (17). As
expected, the atrial rate is increased after atropine injection.
The effect on the atrial repolarization expected from previ-
ous work on the atrial monophasic action potential (38) was
seen. The drug shortened all three atrial intervals, but its
effect on the PTa interval was neutralized by the rate
correction. The effect of atropine on the intervals is ex-
plained by its effect on atrial rate. The drug itself has no
independent effect. This is similar to the ventricular re-
sponse to the drug (38), where atropine shortens the
effective refractory period but does not affect the monopha-
sic action potential; however, the ventricle is predominantly
under the influence of sympathetic tone. This still confirms
the findings of Bisset et al. (7) and contradicts the widely
recognized belief based on animal work that atropine
prolongs atrial refractoriness (39,40).
As would be expected from a beta-adrenoceptor blocking
drug, propranolol slows the atrial rate. Acute administration
of intravenous propranolol has no effect on the uncorrected
atrial intervals but significantly decreases the PTa corrected
for rate change, a finding that has already been documented
for the human ventricle (41). Olsson (42) showed no change
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in duration of atrial monophasic action potentials at 90%
repolarization 10 min after the intravenous administration
of propranolol or alprenolol in 17 patients. Milne et al. (41)
found that propranolol decreased the duration of the QT
interval corrected for rate but increased or did not change
the QT interval duration measured at identical atrial paced
rates. Edvardsson et al. (38) showed no effect of acute
metoprolol on ventricular monophasic action potential du-
ration and refractory periods using similar methods of
constant rates before and after drug administration.
The effects of propranolol and atropine on the atrial ECG
at doses used to create partial or total pharmacologic
autonomic denervation (43,44) are useful to define and
constitute the basis for further studies on autonomic tone at
the atrial level.
Disopyramide is a class Ia antiarrhythmic agent with
combined characteristics of a membrane-stabilizing or local
anesthetic agent (45) and anticholinergic agent (46,47). It
prolongs refractory periods at all levels of the heart and
prolongs the QT interval by prolonging the JT interval (10).
Similarly, at the atrial level, it prolongs the PTa interval
mainly by prolonging the repolarization interval. It does not
modify the atrial rate, and therefore the rate correction
applied is consistent, showing the same prolongation of the
PTa interval. These effects of disopyramide on the atrium
are equivalent to those previously reported for the ventricle
(32).
The electrophysiologic properties of flecainide acetate
have been well documented by a number of authors
(11,48,49). Most studies have used intravenous flecainide at
doses ranging from 1 to 2 mg/kg. It has been shown to
prolong the QT interval by increasing the duration of the
QRS interval without any alteration of the JT interval and
to slightly prolong atrial and ventricular refractory periods
(11,32). The findings in this study for atrial depolarization
and repolarization are similar.
Correction for changes in heart rate using Bazett’s
correction formula adapted to atrial intervals and the
linear regression formula derived here are in agreement.
Another way of testing the correction formula would
have been to study drug effects while maintaining atrial
rate by pacing the atrium. This should be considered in
further studies.
Conclusions. The effect of pacing on atrial ECG was
similar to its effect at a ventricular level on the QRS and QT
intervals and permitted derivation of a rate correction
formula. Using this formula allowed determination of the
intrinsic effect of chronotropic drugs on atrial depolarization
and repolarization. It should also permit future investigation
of the intrinsic effect of biophysical, pharmacologic, patho-
logic phenomena on atrial depolarization and repolariza-
tion, eliminating their potential effect on atrial rate. How-
ever, the correction formula was derived here from the
biophysical effect of pacing, and using it to account for
changes in atrial rate related to autonomic tone, in particular
exercise, should be done cautiously.
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